Short answer
Perspective Therapeutics, Inc. (CATX) filed an 8-K current report with the SEC on November 6, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). New Phase 1/2a VMT-α-NET data and analyses presented at NANETS 2026.
Perspective Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- New Phase 1/2a VMT-α-NET data and analyses presented at NANETS 2026
- Program targets unresectable or metastatic SSTR2-expressing neuroendocrine tumors
- Investor presentation adds program information beyond the conference disclosures
- Clinical updates may influence perceived efficacy, safety, and development prospects for VMT-α-NET
Item EX-99.1 · Exhibit EX-99.1
- Bamzireotide showed 75% 18-month PFS and 95% disease control across 57 SSTR2-positive GEP-NET patients
- Objective response rate reached 39% in the 57-patient enrichment subgroup, supporting potential registration-study patient selection
- Safety remained favorable across 68 treated patients: no dose-limiting toxicities, treatment-related discontinuations, Grade 4 or 5 events
- Grade 3 adverse events affected 20 of 68 patients, while Grade 3 renal events occurred in 2 patients
- End-of-Phase 2 FDA meeting targeted for 1Q 2027, with Phase 3 initiation planned for 2027 pending regulatory feedback and execution needs
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Perspective Therapeutics, Inc. 8-K filings
Get the next CATX 8-K as it lands
Follow CATX for push alerts, or ask the research agent what this filing means.